LNC · Lincoln National Corp. · Stock research

Current Thesis

Two weeks changed the shape of this. On 2026-08-07 the stock closed at $46.03, 2.1% under the $47.00 52-week high, after the entire sell-side marked targets up through July on the Talcott risk-transfer agreement and a Q2 operating beat. On 2026-08-21 it closed at $42.15, 10.3% below that high, with RSI(14) at 29.6. No disclosure has contradicted the narrative leg an investor is buying — Lincoln converting a capital-consuming guaranteed universal life back book into subsidiary cash. What changed is the marginal buyer. On 2026-08-10 the company said CFO Chris Neczypor is leaving (he notified the board 2026-08-06), with Chief Accounting Officer and Treasurer Adam Cohen taking the role on an interim label while a search runs across internal and external candidates. That removed the executive who carried the capital story through the July cession and the Bain Capital partnership. Price has since fallen back through MarketBeat's $43 consensus median (23 analysts, as of 2026-08-04) from above and now trades at the level JPMorgan (Underweight, 2026-07-21) and TD Cowen (Hold, 2026-07-22) each set at $42. The three-month price change is still +18.3%, so the July re-rating is dented, not erased.

Bullish and bearish views on Lincoln National Corp.

The model's bull view on Lincoln National Corp. (LNC), in brief: The balance-sheet event is signed. Announced 2026-07-30: Talcott reinsures ~$5.8B of in-force GUL statutory reserves plus ~$500M of funding agreement liabilities (~$6.3B total per Talcott's release), for an all-in statutory capital impact of ~$200M and roughly 10 RBC points… The bear view: The CFO seat is empty at the moment the capital story needs a narrator. Both cases follow in full.

Bull Case

• The balance-sheet event is signed. Announced 2026-07-30: Talcott reinsures ~$5.8B of in-force GUL statutory reserves plus ~$500M of funding agreement liabilities (~$6.3B total per Talcott's release), for an all-in statutory capital impact of ~$200M and roughly 10 RBC points, with close expected in Q4 2026 subject to regulatory approval. Management guided it to add roughly $30–40M of annual subsidiary remittances over the medium term.
• Q2 2026 (2026-07-30): adjusted operating income available to common of $439M, $2.24 per diluted share, against a $1.96 tracked consensus. Segment operating income: Annuities $287M, Group Protection $147M, Life Insurance $57M, Retirement Plan Services $49M — the earnings base is not concentrated in the block being ceded.
• Capital is being returned, into the drawdown. On 2026-08-09 Lincoln launched concurrent issuer tender offers for up to $500M aggregate liquidation preference of its Series C and Series D depositary shares — Series C at $1,055.00 per $1,000 of liquidation preference, Series D at $26.30 per $25.00 — payable with cash on hand, expiring 5:00 p.m. ET on 2026-09-08 with settlement expected 2026-09-10. On 2026-08-10 the board declared a quarterly cash dividend and said it plans to resume share repurchases in Q3 2026.
• Reported book sits far above the quote. At 2026-06-30, adjusted book value per share was $79.45 and book value per share excluding AOCI was $77.39, against the 2026-08-21 close of $42.15. Estimated RBC was above 420% versus a 400% target plus a 20-point buffer; holding company available liquidity was $903M net of prefunding.
• The July target raises are still on the tape. Mizuho to $53 and KBW to $51 (both Outperform, 2026-07-31), Wells Fargo $47 (2026-07-09), Evercore ISI $51 In-Line (2026-07-13), Barclays upgrade to Overweight at $45 (2026-07-06).

Bear Case

• The CFO seat is empty at the moment the capital story needs a narrator. The 2026-08-10 8-K states the departure is not related to the company's financial or operating results or to any disagreement with management or the board, and Neczypor stayed through the end of August. That still leaves an interim finance chief through the Talcott approval process and the Q3 print. Insurance Business Magazine placed the exit within a run of senior leadership changes at the company (August 2026).
• The re-rating has round-tripped to the bearish targets. From the 2026-08-07 close of $46.03 to the 2026-08-21 close of $42.15, the stock gave back the post-announcement premium and landed on the $42 marks JPMorgan and TD Cowen published on 2026-07-21 and 2026-07-22 — set before the deal was announced.
• The top line missed and the GAAP line is noise. Q2 revenue of $4,542M came in under the $4,905M consensus; net income available to common was $1,321M ($6.72 diluted) against $439M of adjusted operating income, the gap driven by hedging and market-risk-benefit marks.
• The deal is announced, not closed. No scheduled disclosure between now and the Q3 print (~2026-10-29, est.) speaks to the regulatory approval path, and the ~10-point RBC cost lands only on close.
• Book value depends on which line is read. BVPS including AOCI was $53.68 at 2026-06-30 versus $77.39 excluding it — a rate-driven gap that moves against the stock when the long end falls.

Setup & Price Structure

The narrative is saturated. The dates that place it there: every major desk repriced the name between 2026-07-06 (Barclays upgrade, $45) and 2026-07-31 (Mizuho $53, KBW $51); the Bloomberg report of the Talcott talks landed 2026-07-13, seventeen days before the agreement; the print and the deal came the same morning, 2026-07-30. All of that information is public and absorbed. What followed is the observable that matters: the price made its high, then declined into 2026-08-21 with no new sell-side action in the two weeks after the CFO announcement. Mainstream coverage, a full set of raised targets, and a fading bid.

Crowding and positioning observables, stated without a verdict:

• The 2026-08-21 close of $42.15 is 10.3% below the $47.00 52-week high, with RSI(14) at 29.6 — an oversold reading rather than an extended one, which is the opposite footing from the $46.03 close on 2026-08-07.
• Price sits below MarketBeat's $43 consensus median (as of 2026-08-04) after trading above it, with the published target range spanning $35 to $53.
• The company is a buyer of its own preferred securities with cash on hand through 2026-09-08 and has stated an intent to resume common repurchases within Q3 2026. There is no equity issuance into strength in the record reviewed here, and no insider transactions are cited in that record.
• No earnings date falls inside the next 30 days; consensus places the Q3 print near 2026-10-29 with EPS around $2.02.

The structural line is $42: it is where two bearish July targets sit, roughly where the stock traded before the 2026-07-30 announcement, and 0.4% below the last close. A weekly close beneath it completes the give-back of the deal-driven advance.

Catalyst Calendar (next 30 days)

• 2026-09-08 — Expiration of the concurrent tender offers for up to $500M aggregate liquidation preference of Series C and Series D depositary shares, 5:00 p.m. ET.
• 2026-09-10 (expected) — Settlement date for the tender offers. Take-up size shows how much preferred Lincoln actually retires with cash on hand.
• ~2026-08-31 (est., per company) — End of Neczypor's transition period; Adam Cohen carries the CFO role alone from there. A permanent CFO appointment can be announced at any point.
• ~2026-09-30 — Close of Q3 2026, the quarter in which the board said on 2026-08-10 that share repurchases would resume.
• ~2026-10-29 (est.) — Q3 2026 results. Outside the 30-day window, and the next dated event that speaks to the Talcott approval path, the RBC estimate and the remittance trajectory.

What Would Change Our Mind

The structure that has to hold is the pre-announcement shelf around $42 — the level the stock occupied before the 2026-07-30 cession was disclosed and the level JPMorgan and TD Cowen independently published in the week prior. A weekly close below $42 confirms that the deal-driven advance has fully round-tripped and that the July target raises found no follow-through bid; the theme would then be reading as a failed re-rating rather than a saturated one, and the burden shifts to the Q3 print to restart it.

On the other side, the specific datapoints that would rebuild the case: a Talcott closing announcement with an estimated RBC ratio still above 420%; full take-up of the $500M preferred tender at settlement on 2026-09-10 followed by disclosed common repurchases before 2026-09-30; a permanent CFO named with life-insurance capital-management credentials. Conversely, a Q4 2026 close date slipping in Q3 10-Q language, a reserve charge on the retained long-term care or universal life blocks, or Annuities segment operating income printing below the $287M Q2 level would each cut the thesis at a different joint.

Correlation Notes

• Long-end rates drive reported book directly. The $23.71-per-share gap between BVPS excluding AOCI ($77.39) and including it ($53.68) at 2026-06-30 is a duration mark; the name trades with the 10s/30s move alongside other rate-levered life insurers.
• Legacy risk transfer is a sector flow, not a single-company story. The counterparty is Talcott Financial, and Lincoln funded its side partly from proceeds of the Bain Capital partnership. Repricing of that private-capital bid for back books — through a competitor deal on worse terms, or a regulator slowing an approval — reads across.
• Credit spreads sit inside operating income. General-account spread earnings and AOCI both compress when investment-grade spreads widen, hitting the Annuities line and the AOCI-inclusive book at the same time.
• GAAP results carry equity-volatility beta. With Q2 net income to common of $1,321M against $439M of adjusted operating income, the headline number moves with hedging and market-risk-benefit marks and can diverge from the operating trend in either direction.